Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,150,981 papers from all fields of science
Search
Sign In
Create Free Account
Recombinant interferon beta-1a
Known as:
INTERFERON BETA-1A,RECOMBINANT
, Interferon Beta-1A
A synthetic version of naturally occurring interferons that have immunomodulatory, antiviral and antiproliferative activities. It may exert antitumor…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
38 relations
Acquired Immunodeficiency Syndrome
Age related macular degeneration
Autoimmune Diseases
Brain Neoplasms
Expand
Narrower (1)
Rebif
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta
J. Brzoska
,
H. von Eick
,
M. Hündgen
Drug research
2020
Corpus ID: 218857740
The pharmacological and immunological properties of interferons, especially those of interferon beta, and the corresponding…
Expand
Review
2009
Review
2009
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.
H. Hartung
Expert Opinion on Pharmacotherapy
2009
Corpus ID: 30814153
BACKGROUND There is at present no cure for multiple sclerosis (MS), and existing therapies are designed primarily to prevent…
Expand
Review
2009
Review
2009
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis
H. Hartung
2009
Corpus ID: 73029250
Background: There is at present no cure for multiple sclerosis (MS), and existing therapies are designed primarily to prevent…
Expand
2003
2003
Severe urticaria due to recombinant interferon beta‐1a
L. Mazzeo
,
L. Ricciardi
,
+4 authors
S. Isola
British Journal of Dermatology
2003
Corpus ID: 9683260
SIR, A 7-year-old boy with mild eczema was treated with Oilatum Plus (Stiefel, High Wycombe, U.K) and intermittent application of…
Expand
2002
2002
Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study.
L. Kowalzick
,
T. Rogoziński
,
+10 authors
S. Jabłońska
EJD. European journal of dermatology
2002
Corpus ID: 9599878
Although effective conventional therapies are available to treat basal cell carcinoma (BCC), undesirable side effects, including…
Expand
2000
2000
A randomized controlled trial of recombinant interferon beta-1a in ALS
E. Beghi
,
A. Chiò
,
+8 authors
P. Tonali
Neurology
2000
Corpus ID: 71317805
Objective: To evaluate the efficacy of recombinant interferon beta (IFNβ)-1a in the treatment of ALS. Background: It has been…
Expand
2000
2000
A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Study Group.
E. Beghi
,
A. Chiò
,
+8 authors
P. Tonali
Neurology
2000
Corpus ID: 12419542
OBJECTIVE To evaluate the efficacy of recombinant interferon beta (IFNbeta)-1a in the treatment of ALS. BACKGROUND It has been…
Expand
2000
2000
A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C.
F. Habersetzer
,
N. Boyer
,
+5 authors
C. Trépo
Liver
2000
Corpus ID: 23847241
AIMS Interferon alpha monotherapy induces a sustained response in less than 20% of patients treated for chronic hepatitis C…
Expand
Highly Cited
1995
Highly Cited
1995
A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients
L. Jacobs
,
D. Cookfair
,
+23 authors
R. Whitham
1995
Corpus ID: 53906738
The design and conduct of a randomized, double-blinded, placebo-controlled, multicenter, phase III study of recombinant…
Expand
1995
1995
A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients…
L. Jacobs
,
D. Cookfair
,
+7 authors
J. Simon
Multiple Sclerosis
1995
Corpus ID: 30064140
The design and conduct of a randomized, double-blinded, placebo-controlled, multicenter, phase III study of recombinant…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE